BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Information Letter on clopidogrel: Risk of acquired haemophilia

Active substance: clopidogrel

The marketing authorisation holders are circulating information on a small number of cases of acquired haemophilia associated with clopidogrel treatment in patients without a history of haemostasis.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 145KB, File is accessible